- In June 2024, Lacrifill, a canalicular gel device, was introduced in the US as an effective, safe, and well-tolerated treatment for dry eye. The device occludes the canalicular system, offering a novel alternative to punctal plugs with minimal side effects and a six-month duration.
- In December 2023, Nordic Pharma, through its subsidiary Amring Pharmaceuticals, has acquired Visant Medical and plans to launch the Lacrifill canalicular occlusive device for dry eye disease (DED) in the United States. The FDA-cleared device temporarily blocks tear drainage by occluding the canalicular system. Nordic aims to introduce Lacrifill to U.S. ophthalmologists and optometrists treating over 16 million DED patients, with a goal to make it the standard for preoperative care. Following the U.S. launch in 2024, Nordic plans to seek global regulatory approval.
- In June 2023, Novartis has agreed to divest its 'front of eye' ophthalmology assets to Bausch + Lomb for up to USD 2.5 billion, including Xiidra for dry eye disease and SAF312 (libvatrep) for chronic ocular surface pain. This aligns with Novartis' strategy to focus on prioritized therapeutic areas. The deal also includes milestone payments up to USD 750 million and a transitional supply agreement for Xiidra. Novartis will continue its research on retinal diseases through platforms such as gene therapy and optogenetics.
- In December 2022, China Pharma Holdings has acquired a patented therapeutic device for dry eye disease (DED). With DED affecting 25-30% of the population, and 75% of those over 65 in China, the acquisition targets a growing market. The device, designed for treating DED, visual fatigue, and aiding recovery post-eye surgery, fills a gap in the market for medical therapeutic devices. China Pharma aims to launch the device next year, expecting it to enhance treatment experiences for patients and drive company sales growth.
